Overview

A Extension Study of Udenafil in Adolescents

Status:
Active, not recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This study is a 12-month (52 week) safety extension study to supplement the FUEL Phase III clinical trial to provide safety information regarding the long-term use of udenafil in adolescents with single ventricle congenital heart disease.

Phase:

Phase 3

Details

Lead Sponsor:

Mezzion Pharma Co. Ltd

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Udenafil